Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen

J Clin Oncol. 2010 Oct 10;28(29):e584-5; author reply e586. doi: 10.1200/JCO.2010.30.1887. Epub 2010 Sep 7.

Authors

Roberta Ferraldeschi, Sacha J Howell, Alastair M Thompson, William G Newman

PMID: 20823421
DOI: 10.1200/JCO.2010.30.1887

No abstract available

Publication types

Comment
Letter

MeSH terms

Antineoplastic Agents, Hormonal / metabolism
Antineoplastic Agents, Hormonal / therapeutic use
Breast Neoplasms / drug therapy*
Breast Neoplasms / enzymology
Breast Neoplasms / pathology
Breast Neoplasms, Male / drug therapy*
Breast Neoplasms, Male / enzymology
Breast Neoplasms, Male / pathology
Cytochrome P-450 CYP2D6 / metabolism
Cytochrome P-450 CYP2D6 Inhibitors*
Disease-Free Survival
Enzyme Inhibitors / therapeutic use*
Female
Humans
Male
Medication Adherence
Neoplasm Recurrence, Local
Risk Assessment
Risk Factors
Tamoxifen / metabolism
Tamoxifen / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents, Hormonal
Cytochrome P-450 CYP2D6 Inhibitors
Enzyme Inhibitors
Tamoxifen
Cytochrome P-450 CYP2D6